Please assess the completion status of the following clinical trial:

Trial Title: Levetiracetam Treatment of Neonatal Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Neonatal seizure occurred and was proved by EEG according to abnormal discharge of brain. one or more of the following :~1. Male or female term baby with gestational \>37 weeks and postnatal age \< or= 28 days~2. Birthweight \>2500g~3. Written informed consent of parent or guardian~Exclusion Criteria:~1. Babies who have been close to death~2. Seizure occurred by metabolic factors (hypoglycemia, hypocalcemia, electrolyte disorder)~3. Babies who have received phenobarbitone or any other anticonvulsive medication before hospitalization~4. Abnormal renal function

- Gender: ALL
- Minimum Age: None
- Maximum Age: 28 Days
- Healthy Volunteers: f

Study Arms:
- Oral levetiracetam (Type: EXPERIMENTAL): Oral levetiracetam 50 mg/kg loading dose. 10 mg/kg 8 hourly maintenance
- Intravenous phenobarbital (Type: ACTIVE_COMPARATOR): Intravenous phenobarbital 20 loading dose (add to 40 mg/kg if seizure discontrol). 5 mg/kg 24 hourly maintenance

Based on this trial design, predict the completion outcome and termination type (if applicable).